Wellness brand Maxine+Morgan is launching a clinical study to investigate the effectiveness of its custom herbal blend of CBD, turmeric, ginger and other natural ingredients for menstrual symptom relief.
In a three-month long, blind placebo-controlled study, participants will record their pain levels and quality of life twice a day.
At random, the 70 participants will receive a Maxine+Morgan herbal supplement, Ibuprofen, and placebo in order to compare results.
"With the clinical study, we're hoping to continue the conversation around women's wellness and ways in which we can use the amazing healing qualities of naturally derived herbs to influence an uninterrupted lifestyle,” Ariel Morgan, CEO and president of Maxine+Morgan, told Benzinga. “It's important to us that we leverage our resources and invest in research, analysis and experiential data to efficiently support our consumers needs.”
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
